<DOC>
	<DOCNO>NCT01389193</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled , two period cross study ibudilast treatment chronic migraine . For participant resident Adelaide , South Australia ( i.e . `` local participant '' ) : The study involve screen visit follow eight visit Pain Anaesthesia Research Clinic ( PARC ) , within Royal Adelaide Hospital ( RAH ) , baseline testing , initiation study medication ongoing data collection ( one baseline three study visit treatment period ) . At baseline visit , blood sample assess biomarkers ( glutamate , calcitonin gene-related peptide , glial fibrillary acidic protein S100β ) take . Patients randomise ( 1:1 ratio ) commence either ibudilast placebo treatment , continue 8 week . Subsequently participants undergo 4-week washout period . At end washout period second 8-week treatment block alternative treatment commence . Patients complete headache diary daily least 4 week prior baseline visit , throughout treatment washout period 4 week treatment cease . The diary record headache frequency , duration , intensity , pain characteristic medication intake comparison baseline data . From screen final study visit ( minimum 6 month ) total approximately 200 mL blood sample take local participant . For participant located country interstate location : The study undertaken , instead attend Pain Anaesthesia Research Clinic ( PARC ) , within Royal Adelaide Hospital ( RAH ) screen study visit , manage remotely : basic input participant 's GP screening period correspondence PI study staff via registered post , phone Skype schedule visit near pathology collection centre blood biochemistry haematology analysis Interstate country participant also exempt collection blood sample biomarker analysis , hence total approximately 120 mL blood sample take interstate country participant .</brief_summary>
	<brief_title>Ibudilast Treatment Patients With Chronic Migraine .</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ibudilast</mesh_term>
	<criteria>Men woman age 18 65 year Migraine without aura , diagnose accord second edition International Classification Headache Disorders ( ICHDII ) Onset migraine 50 year age Headache 15 day per month Migrainelike headache 8 day per month , per IHS guideline Change type dose migraine prophylactic medication last 3 month Medication overuse headache diagnose accord ICHDIIR Posttraumatic headache diagnose accord ICHDII Other dominant chronic pain condition Known active inflammatory disease rheumatoid arthritis History recent cerebrovascular disorder Unable provide write informed consent Unable read write English Severe psychological/psychiatric disorder Recent history significant trauma , determine Principal Investigator include major surgery within previous 2 month major surgery plan treatment period Recent history drug alcohol abuse Any clinically significant finding screen blood sample result Current malignancy Known hypersensitivity ibudilast excipients Ketas® formulation Renal hepatic impairment , define baseline GFR ( calculate CockcroftGault equation ) &lt; 60 mL/min , LFTs ( exclude bilirubin ) &gt; 3 time upper limit normal bilirubin &gt; 2 time upper limit normal For female childbearing potential : Pregnancy Lack adequate contraception ( abstinence , double barrier method , intrauterine device , surgical sterilization ( self partner ) , hormonal contraceptive method ( oral , injected , implant ) Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ibudilast</keyword>
	<keyword>migraine</keyword>
	<keyword>glial cell</keyword>
</DOC>